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EPLY
n our study (1) we observed a reduced incidence of atrial
brillation (AF) following coronary artery bypass surgery in pa-
ients receiving polyunsaturated fatty acids (PUFAs). The way
hese compounds could have determined this result is, at present,
nly speculative. Indeed, PUFAs have been demonstrated to have
direct anti-arrhythmic effect in different laboratory models, but
he importance of a concurrent (or prevalent) anti-inflammatory
ction cannot be excluded. In fact, PUFAs have anti-inflammatory
roperties (2), and inflammation, as correctly pointed out by Dr.
orantzopoulos and colleagues can play a fundamental role in
ostcardiac surgery AF. Actually, the efficacy of an anti-inflammatory
herapy in this setting is still not clear owing to conflicting reports.
hereas a single postinduction steroid administration was shown
o prevent postoperative AF (3), a similar protocol was found
neffective in other hands (4). The debate on this subject is thus
till open, but unfortunately a further contribution cannot be
btained by our study, because C-reactive protein (CRP) levels or
ther inflammatory indexes were not routinely collected in our
atients.
Concerning off-pump surgery that could carry a lower risk of
F due to a lesser oxidative and inflammatory response, aside from
eports supporting this assumption (5) there are other studies that
o not confirm this finding (6). In our study the incidence of AF
as similar in patients receiving off-pump surgery (26.3% of 19
ases) and those submitted to on-pump surgery (24.1% of 141
ases). However, our population is too scarce to draw any conclu-
ion on this subject.
Statins have been reported to prevent AF both after cardiac
urgery (7) and after electrical cardioversion (8), possibly by their
leiotropic anti-inflammatory action. In our examination we did
ot observe any difference in AF incidence between patients on
tatins (24.2% of 91 patients) and those not on statins (24.6% of 61
atients). This could be due to the fact that the mean dose of
tatins in our patients was low (15.3 9.2 mg/day simvastatin and
3.2  7.5 mg/day atorvastatin) and the anti-inflammatory and
hus, possibly, anti-arrhythmic effect of statins seems to be related
o the dose. In fact, a recent study reported a significant decrease
f CPR (36.4%) with atorvastatin 80 mg but not with pravastatin
0 mg (5.2%) (9).
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erum Erythropoietin Levels and Infarct Size
ith great interest we read the recent study by Namiuchi et al. (1)
howing an association between high serum erythropoietin levels
nd smaller infarct size in patients with acute myocardial infarction
MI) undergoing primary angioplasty.
Although originally considered a hematopoietic hormone,
rythropoietin (EPO) has been shown to act as a pleiotropic
urvival and growth factor (2). There is accumulating evidence for
protective role of EPO in the heart. We and others have
emonstrated that exogenous EPO administration in rodent
schemia-reperfusion models leads to reduced infarct size and
nhibition of apoptosis (3,4).
Namiuchi et al. (1) suggested that endogenous EPO might also be
rotective against ischemia-reperfusion injury in humans. However,
levated EPO levels could also be a direct reflection of the disease
everity. Serum EPO is elevated in chronic heart failure (CHF)
atients, and this increase is related to the progression of the disease
5). Our group has shown that, in these patients, elevated plasma
PO levels are associated with an impaired prognosis, independent of
emoglobin levels and other established markers of CHF severity (6).
f note, in the study by Namiuchi et al. (1), MI patients with higher
PO levels were found to have significantly higher serum levels of
-type natriuretic peptide (BNP), a sign of hemodynamic impair-
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January 17, 2006:464–71ent. Enhanced production of EPO could therefore also serve as a
ompensatory mechanism under ischemic conditions and reflect the
everity of ischemic injury.
In the present study, patients with higher EPO levels and
maller infarct size also had lower hemoglobin levels. This is in
ontrast to previous findings, namely that a low hemoglobin
oncentration is associated with higher mortality in patients with
table coronary artery disease (7) and acute MI (8).
In addition, a very weak correlation between enzymatic infarct
ize and endogenous EPO levels should awake cautiousness as to
he interpretation of the presumed effect of endogenous EPO on
educing the infarct size. Moreover, the serum EPO levels were
easured almost 10 hours after the angioplasty and could thus
eflect peri- and postprocedural blood loss, or ischemia-triggered
PO production.
Finally, we believe that the potential mechanism of protective
PO action in these patients might be different from that
uggested by the investigators. In an acute ischemic situation,
escuing the cardiomyocytes from cell death (apoptosis) seems a
ore plausible explanation than increased neovascularization
hrough progenitor cell stimulation. Further studies in larger
ohorts of patients should elucidate the precise role of endogenous
PO in acute coronary syndromes. Moreover, therapy of patients
ith MI with exogenous EPO may be considered in the future.
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e appreciate the interest and thoughtful comments of Dr. Lipsic
nd colleagues regarding our study (1). The conclusions of our
tudy were that a higher endogenous erythropoietin (EPO) level
an predict a smaller infarct size in patients with acute myocardial
nfarction (MI) subjected to successful primary percutaneous
oronary intervention (PCI), and that this might be attributed to
he potentially protective effect of endogenous EPO against
schemia-reperfusion injury in humans. As pointed out by Dr.
ipsic and colleagues, these conclusions may be in contrast to
hose of studies by Dr. Lipsic and colleagues (2) and by others as
ell (3). They reported that a lower hemoglobin content was
ssociated with higher mortality in patients with acute MI (2) and
table coronary artery disease (CAD) (3). We would like to
mphasize, however, that in our study the hemoglobin concentra-
ion was not an independent predictor of the infarct size, whereas
he endogenous EPO level was. We believe that we cannot directly
ompare the results of our study with those of the two studies by
r. Lipsic and colleagues and by others because they did not
easure the serum EPO level in their patients.
Dr. Lipsic and colleagues also reported that, in patients with
hronic heart failure, elevated plasma EPO levels are associated
ith an impaired prognosis (4). The mechanisms of the increased
lasma EPO levels in some patients with chronic heart failure are
till unclear, and they may be different from those in the patients
ith acute MI in our study. As described in our report (1), it is
ossible that current smoking increased the hemoglobin content in
he blood and affected the serum EPO levels of the patients in the
ow EPO group. With regard to the timing of the blood sampling
or the serum EPO level, we collected the blood samples 9.9 
.2 h after the onset of acute MI as described in the Methods
ection of our study. We believe that Dr. Lipsic and colleagues
isunderstood this issue.
We agree with the investigators that a future study with a larger
umber of patients is needed to draw a more definitive conclusion
egarding the role of endogenous EPO in acute MI.
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